Switzerland-based multinational pharmaceutical company Novartis is acquiring Nasdaq-listed Tourmaline Bio, a US-based clinical-stage biopharmaceutical company focused on developing pacibekitug, an anti-IL-6 mAb, as a treatment option for atherosclerotic cardiovascular disease. Holders…
Switzerland: Novartis to acquire Tourmaline Bio for US$1.4bn
…
…






